Gemini Therapeutics, Inc.

NasdaqGM:GMTX Stock Report

Mkt Cap: US$58.5m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Gemini Therapeutics Future Growth

How is Gemini Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


20.9%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

NasdaqGM:GMTX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2024N/A-14-12N/A1
12/31/2023N/A-14-12N/A1
9/30/2022N/A-43-43-43N/A
6/30/2022N/A-59-55-55N/A
3/31/2022N/A-68-61-61N/A
12/31/2021N/A-72-60-60N/A
9/30/2021N/A-68-56-56N/A
6/30/2021N/A-60-47-47N/A
3/31/2021N/A-50-38-38N/A
12/31/2020N/A-41-33-33N/A
9/30/2020N/A-36-35-35N/A
6/30/2020N/A-37-37-37N/A
3/31/2020N/A-41-39-39N/A
12/31/2019N/A-41-39-39N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GMTX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GMTX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GMTX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if GMTX's revenue is forecast to grow faster than the US market.

High Growth Revenue: GMTX is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if GMTX's Return on Equity is forecast to be high in 3 years time


Discover growth companies